Effect of high-dose ibuprofen in patients with cystic fibrosis

DOI: 10.1056/nejm199503303321303
New England Journal of Medicine, 1995, 332, 848-54.

#	Paper	IF	Citations
705	Saturday's children. **1995**, 152, 1-2		7
704	Anti-inflammatory and antipyretic analgesics and drugs used in gout. **1995**, 19, 92-103		
703	News for the practitioner. **1995**, 154, 684-685		
702	Correspondence. **1995**, 19, 320-322		
701	Selected abstracts. **1995**, 19, 320-322		
700	Symposium session summaries. **1995**, 20, 69-177		
699	Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. **1995**, 21, 839-49; quiz 850-1		52
698	Clearance of HIV--lessons from newborns. *New England Journal of Medicine*, **1995**, 332, 883-4	59.2	6
697	Colon-cancer genes and brain tumors. *New England Journal of Medicine*, **1995**, 332, 884-5	59.2	21
696	Airway inflammation in cystic fibrosis. *New England Journal of Medicine*, **1995**, 332, 886-7	59.2	6
695	Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma. *New England Journal of Medicine*, **1995**, 333, 727; author reply 730	59.2	
694	Transplantation of fetal mesencephalic tissue in Parkinson's disease. *New England Journal of Medicine*, **1995**, 333, 730-1	59.2	15
693	Ibuprofen in patients with cystic fibrosis. *New England Journal of Medicine*, **1995**, 333, 731; author reply 732	59.2	1
692	Serum antibodies to the deleted dystrophin sequence after cardiac transplantation in a patient with Becker's muscular dystrophy. *New England Journal of Medicine*, **1995**, 333, 732-3	59.2	18
691	Cost sharing in health insurance. *New England Journal of Medicine*, **1995**, 333, 733-4	59.2	14
690	More on smoking superheroes. *New England Journal of Medicine*, **1995**, 333, 734	59.2	1
689	Drug management of noninfective complications of cystic fibrosis. **1995**, 50, 626-35		5

688	Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis. **1995**, 127, 881-7		62
687	Infections in cystic fibrosis. **1995**, 6, 174-181		1
686	Animal studies of cystic fibrosis. **1995**, 1, 336-42		3
685	TREATMENT OF STEROID-RESISTANT ASTHMA. **1996**, 16, 777-796		4
684	Management of pulmonary disease in patients with cystic fibrosis. *New England Journal of Medicine*, **1996**, 335, 179-88	59.2	412
683	[Mucoviscidosis: anti-inflammatory therapeutic strategies]. **1996**, 3 Suppl 1, 112s-113s		
682	Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells. **1996**, 58, 2167-81		50
681	Cystic fibrosis-drug therapy. **1996**, 10, 127-34		1
680	Cystic fibrosis. **1996**, 154, 1229-56		778
679	Inflammation in cystic fibrosis. **1996**, 5, 121-43		
678	L'inflammation dans la Mucoviscidose. **1996**, 5, 144-69		1
677	Supplementation with carotenoids corrects increased lipid peroxidation in children with cystic fibrosis. **1996**, 64, 87-93		72
676	Antineutrophil Cytoplasmic Autoantibodies with Specificity Other Than PR3 and MPO (X-ANCA). **1996**, 68-73		2
675	Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. **1996**, 89, 259-65		99
674	Neutrophil proteinases and rhDNase therapy in cystic fibrosis. **1996**, 9, 2193-5		11
673	Liposomal DNA vectors for cystic fibrosis gene therapy. Current applications, limitations, and future directions. **1996**, 19, 73-87		24
672	Bronchiectasis and related disorders. **1996**, 1, 107-14		6
671	Bronchiectasis: a neglected cause of respiratory morbidity and mortality. **1996**, 1, 221-5		37

670	Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: experimental studies in animals. **1996**, 63, 5-42	16
669	Denmark to the rescue. **1996**, 21, 151-2	9
668	Analysis of ibuprofen in serum by capillary electrophoresis. **1996**, 683, 115-8	34
667	Mechanisms of airway inflammation in cystic fibrosis. **1996**, 7, 63-6	4
666	Anti-inflammatory therapy in cystic fibrosis. **1996**, 7, 70-3	1
665	Management of the Child With Cystic Fibrosis. **1996**, 9, 75-90	
664	Relationship between disease severity and inflammatory markers in cystic fibrosis. **1996**, 75, 498-501	29
663	Reduced upper airway nitric oxide in cystic fibrosis. **1996**, 75, 319-22	198
662	Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. **1996**, 26, 25-34	35
661	Opportunities for the use of aerosolized alpha 1-antitrypsin for the treatment of cystic fibrosis. **1996**, 110, 256S-260S	14
660	Anti-inflammatory and antipyretic analgesics and drugs used in gout. **1997**, 20, 86-102	
659	Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection. **1997**, 156, 1190-6	65
658	Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. **1997**, 77, 124-30	76
657	Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. **1997**, 175, 638-47	212
656	Immunologic Aspects of Lung Diseases and Cystic Fibrosis. **1997**, 278, 1924	22
655	New treatments in adult cystic fibrosis. **1997**, 90 Suppl 31, 2-5	0
654	Early inflammation and the development of pulmonary disease in cystic fibrosis. **1997**, 16, 267-8	14
653	[New prospects in cystic fibrosis treatment]. **1997**, 33, 190-5	

652	Concern over ibuprofen/pancreatic enzyme interaction. **1997**, &NA;, 2	
651	The biogenesis, traffic, and function of the cystic fibrosis transmembrane conductance regulator. **1997**, 172, 193-241	36
650	The decline and fall of pulmonary function in cystic fibrosis: new models, new lessons. **1997**, 131, 789-90	19
649	Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. **1997**, 131, 809-14	281
648	Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells. **1997**, 16, 749-59	53
647	Cystic fibrosis: a changing clinical perspective. **1997**, 27, 6-11	4
646	Applied pharmacology in pediatric pain management. **1997**, 1, 296-309	1
645	Measurement of plasma ibuprofen by gas chromatography-mass spectrometry. **1997**, 11, 336-9	19
644	Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. **1997**, 24, 137-42; discussion 159-61	242
643	Implications of early inflammation and infection in cystic fibrosis: a review of new and potential interventions. **1997**, 24, 143-5; discussion 159-61	11
642	Indomethacin and pancreatic enzymes synergistically damage intestine of rats. **1998**, 43, 2322-32	12
641	Prospects for gene therapy for cystic fibrosis. **1998**, 4, 292-9	16
640	Evidence-based pediatric pulmonary medicine: how can it help?. **1998**, 25, 118-27	6
639	Evidence-based medicine. **1998**, 26, 231-3	
638	Response to evidence-based medicine. **1998**, 26, 232-232	
637	Response to Dr. Marino. **1998**, 26, 232-233	
636	Serum eosinophil cationic protein, eosinophil protein X and eosinophil peroxidase in relation to pulmonary function in cystic fibrosis. **1998**, 28, 241-8	23
635	Cystic fibrosis. **1998**, 351, 277-82	155

634	[Mucoviscidosis: therapeutic strategies are multiplying]. **1998**, 5, 1246-52		3
633	Les explorations fonctionnelles respiratoires dans la mucoviscidose. **1998**, 5, 132s-134s		
632	Relationship between socioeconomic status and disease severity in cystic fibrosis. **1998**, 132, 260-4		76
631	Destruction and loss of bronchial cartilage in cystic fibrosis. **1998**, 29, 65-73		29
630	Basic therapies in cystic fibrosis. Does standard therapy work?. **1998**, 19, 487-504, vi		23
629	Ongoing planned clinical trials investigating the pulmonary management of cystic fibrosis. **1998**, 7, 91-8		
628	Carrier screening for cystic fibrosis: costs and clinical outcomes. **1998**, 18, 202-12		285
627	The management of young adults with cystic fibrosis: genes, jeans and genies. **1998**, 20, 217-25		12
626	Cystic fibrosis: a multiple exocrinopathy caused by dysfunctions in a multifunctional transport protein. **1998**, 104, 576-90		33
625	Clinical pharmacokinetics of ibuprofen. The first 30 years. **1998**, 34, 101-54		304
624	Therapies aimed at airway inflammation in cystic fibrosis. **1998**, 19, 505-13, vi		28
623	Obesity. *New England Journal of Medicine*, **1998**, 338, 64; author reply 65	59.2	3
622	Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. **1998**, 97, 1095-102		205
621	Meta-analyses and large randomized, controlled trials. *New England Journal of Medicine*, **1998**, 338, 59; author reply 61-2	59.2	28
620	Hormone-replacement therapy compared with simvastatin for postmenopausal women with hypercholesterolemia. *New England Journal of Medicine*, **1998**, 338, 63; author reply 64	59.2	4
619	Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. *New England Journal of Medicine*, **1998**, 338, 65-6	59.2	55
618	Case 21-1997: Paraneoplastic cerebellar degeneration and Hodgkin's disease. *New England Journal of Medicine*, **1998**, 338, 66	59.2	
617	Professionalism. *New England Journal of Medicine*, **1998**, 338, 66-66	59.2	0

616	Lung infections. 3. Pseudomonas aeruginosa and other related species. **1998**, 53, 213-9	69
615	Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. **1998**, 113, 1235-43	77
614	Effect of dirithromycin on Haemophilus influenzae infection of the respiratory mucosa. **1998**, 42, 772-8	15
613	Update on clinical trials in the treatment of pulmonary disease in patients with cystic fibrosis. **1999**, 8, 1917-1927	
612	IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. **1999**, 160, 2040-7	108
611	Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report. **1999**, 8, 13-5	15
610	Inflammation and CFTR: might neutrophils be the key in cystic fibrosis?. **1999**, 8, 7-11	33
609	Aspirin and some other nonsteroidal anti-inflammatory drugs inhibit cystic fibrosis transmembrane conductance regulator protein gene expression in T-84 cells. **1999**, 8, 219-27	10
608	Priming of blood neutrophils in children with cystic fibrosis: correlation between functional and phenotypic expression of opsonin receptors before and after platelet-activating factor priming. **1999**, 179, 151-62	26
607	Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. **2000**, CD001505	10
606	Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. **1999**, 160, 186-91	310
605	Quantitative and qualitative differences in bronchoalveolar inflammatory cells in Pseudomonas aeruginosa-resistant and -susceptible mice. **1999**, 115, 103-9	34
604	rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease. **1999**, 24, 415-26	20
603	Update and Review: Cystic Fibrosis. **1999**, 8, 137-62	4
602	Pyloric channel stricture secondary to high-dose ibuprofen therapy in a patient with cystic fibrosis. **1999**, 33, 693-6	12
601	High-resolution computed tomography of the chest in children with cystic fibrosis: support for use as an outcome surrogate. **1999**, 29, 731-5	113
600	Pharmacokinetics of ibuprofen in patients with cystic fibrosis. **1999**, 19, 340-5	13
599	Ibuprofen: new explanation for an old phenomenon. **1999**, 57, 313-20	63

598	Rheumatic disease and cystic fibrosis. **1999**, 42, 1563-71	24
597	Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. **1999**, 28, 248-54	72
596	Direct injection HPLC analysis of some non-steroidal anti-inflammatory drugs on restricted access media columns. **1999**, 13, 51-6	22
595	Abstruse comparisons: the problems of numerical contrasts of two groups. **1999**, 52, 13-8	10
594	The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. **1999**, 134, 58-63	32
593	Goals of therapy in antibody deficiency syndromes. **1999**, 104, 911-3	10
592	Pulmonary abnormalities in patients with primary hypogammaglobulinemia. **1999**, 104, 1031-6	150
591	Dornase alpha and survival of patients with cystic fibrosis. **1999**, 60, 736-9	2
590	The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. **1999**, 115, 1053-8	79
589	Emerging therapies for cystic fibrosis lung disease. **1999**, 115, 1120-6	38
588	Lymphocyte glutathione levels in children with cystic fibrosis. **1999**, 116, 201-5	40
587	Pharmacokinetics of ibuprofen enantiomers in children with cystic fibrosis. **2000**, 40, 861-8	10
586	Cartilaginous airway wall dimensions and airway resistance in cystic fibrosis lungs. **2000**, 15, 735-42	60
585	Selectivity of cyclo-oxygenase inhibitors in human pulmonary epithelial and smooth muscle cells. **2000**, 15, 751-6	25
584	Prenatal Smoking Increases Risk of Cleft Lip/Palate. **2000**, 3, 61-62	
583	Diagnosis and treatment of cystic fibrosis. **2000**, 67, 239-47	74
582	Re: Rost et al. describing the effects of neck position on endotracheal tube (ETT) location in low birth weight infants. **2000**, 29, 242-4	1
581	The authors respond. **2000**, 29, 243-244	

580	Role of progestational agents in the treatment of undernourished patients with cystic fibrosis. **2000**, 29, 244		13
579	Ibuprofen therapy in cystic fibrosis. **2000**, 29, 244-5		2
578	Response by author. **2000**, 29, 245		
577	Modern statistical techniques for the analysis of longitudinal data in biomedical research. **2000**, 30, 330-44		135
576	Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis. **2000**, 30, 413-24		47
575	Activation of human CIC-2 Cl- channels: implications for cystic fibrosis. **2000**, 27, 896-900		10
574	Ibuprofen use to reduce the incidence and severity of bronchopulmonary dysplasia: a pilot study. **2000**, 20, 13-6		21
573	Neutrophils: molecules, functions and pathophysiological aspects. **2000**, 80, 617-53		792
572	PKA and arachidonic acid activation of human recombinant ClC-2 chloride channels. **2000**, 279, C40-50		63
571	Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection?. **2000**, 161, 641-5		135
570	Chest pain in women with normal coronary angiograms. *New England Journal of Medicine*, **2000**, 342, 885-7	59.2	28
569	Growth in children with chronic lung disease. *New England Journal of Medicine*, **2000**, 342, 887-8	59.2	14
568	Clinical implications of inflammation in young children. **2000**, 162, S11-4		12
567	In vivo lipid peroxidation and platelet activation in cystic fibrosis. **2000**, 162, 1195-201		77
566	Transport of bifunctional proteins across respiratory epithelial cells via the polymeric immunoglobulin receptor. **2000**, 161, 944-51		19
565	Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. **2000**, 161, 271-9		91
564	Diagnosis of lung cancer: FOB before CT or CT before FOB?. **2000**, 55, 350-1		2
563	CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. **2000**, 68, 4289-96		233

562	Maintenance treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis. **2000**, 55, 349-50	22
561	Superantigens and cystic fibrosis: resistance of presenting cells to dexamethasone. **2000**, 7, 553-6	7
560	Maternal Anticonvulsant Therapy and Neonatal Blood Coagulation. **2000**, 3, 62-63	
559	Role of bronchial responsiveness testing in asthma prevalence surveys. **2000**, 55, 352-4	30
558	Inflammation in cystic fibrosis and its management. **2000**, 1, 101-6	26
557	Newer therapies for cystic fibrosis. **2000**, 1, 107-13	1
556	A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. **2000**, 136, 304-10	206
555	[Correction of CFTR anomalies: pharmacological approach]. **2000**, 7 Suppl 2, 352s-354s	
554	Statistical analysis of the long-term effects of recombinant human deoxyribonuclease on pulmonary function in cystic fibrosis patients. **2000**, 10, 287-97	1
553	Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. **2000**, 2, 451-63	35
552	New and emerging therapies for pulmonary complications of cystic fibrosis. **2001**, 61, 1379-85	8
551	[SEPAR (Spanish Society of Pneumology and Thoracic Surgery) Guidelines. Guideline for diagnosis and treatment of respiratory involvements in cystic fibrosis]. **2001**, 37, 316-24	25
550	Utilizaci□ de la alternancia de antipir□icos en el tratamiento de la fiebre en Espa□. **2001**, 55, 503-510	6
549	Antipyretics: mechanisms of action and clinical use in fever suppression. **2001**, 111, 304-15	184
548	Defining a pulmonary exacerbation in cystic fibrosis. **2001**, 139, 359-65	219
547	A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. **2001**, 139, 813-20	235
546	What is the cystic fibrosis clinician supposed to do with human recombinant dornase alfa?. **2001**, 139, 768-70	3
545	[Management of pulmonary involvement in mucoviscidosis in the child]. **2001**, 8 Suppl 5, 856s-883s	1

544	Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery. **2001**, 1, 223-38	8
543	Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. **2001**, 3, 817-58	101
542	CFTR and pseudomonas infections in cystic fibrosis. **2001**, 6, d890-897	6
541	Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. **2001**, 280, L493-502	147
540	CFTR and pseudomonas infections in cystic fibrosis. **2001**, 6, D890-7	17
539	Bacterial infections and inflammation in the lungs of cystic fibrosis patients. **2001**, 20, 207-13	27
538	Inpatient care of the adult with an exacerbation of cystic fibrosis. **2001**, 12, 293-304	3
537	Bronchiectasis. **2001**, 14, 193-7	17
536	Inflammation and infection in cystic fibrosis--hen or egg?. **2001**, 17, 4-5	6
535	Pulmonale Manifestation der Zystischen Fibrose. **2001**, 149, 222-238	4
534	Leukotrienes and cystic fibrosis. **2001**, 1, 175-177	
533	Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. **2001**, 3, 23-35	303
532	Effect of choice of reference equation on analysis of pulmonary function in cystic fibrosis patients. **2001**, 31, 227-37	47
531	Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen. **2001**, 31, 314-6	30
530	Gene therapy for cystic fibrosis. **2001**, 3, 409-17	51
529	Inflammation and cystic fibrosis pulmonary disease. **2001**, 21, 593-603	12
528	Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. **2001**, 276, 35494-9	130
527	P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. **2001**, 45, 3437-44	79

526	Ursodeoxycholic acid ameliorates ibuprofen-induced enteropathy in the rat. **2001**, 32, 270-3	9
525	Administration of aerosolized antibiotics in cystic fibrosis patients. **2001**, 120, 107S-113S	71
524	Cystic fibrosis. **2001**, 56, 237-41	46
523	Management of Pulmonary Disease in Patients with Cystic Fibrosis. **2001**, 14, 207-227	2
522	Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists. **2001**, 25, 196-202	28
521	The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. **2001**, 163, 1331-7	242
520	Fitness, acute exercise, and anabolic and catabolic mediators in cystic fibrosis. **2001**, 164, 1432-7	64
519	The human ATP-binding cassette transporter genes: from the bench to the bedside. **2001**, 1, 45-65	121
518	The pharmacokinetics of colistin in patients with cystic fibrosis. **2001**, 41, 645-54	110
517	The Pseudomonas autoinducer N-(3-oxododecanoyl) homoserine lactone induces cyclooxygenase-2 and prostaglandin E2 production in human lung fibroblasts: implications for inflammation. **2002**, 169, 2636-42	135
516	Nutrition and growth in cystic fibrosis. **2002**, 58 Suppl 1, 16-20	17
515	Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis. **2002**, 166, 1248-56	104
514	Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. **2002**, 165, 495-500	74
513	Murine models of CF airway infection and inflammation. **2002**, 70, 495-515	7
512	Global genomic analysis of AlgU (sigma(E))-dependent promoters (sigmulon) in Pseudomonas aeruginosa and implications for inflammatory processes in cystic fibrosis. **2002**, 184, 1057-64	90
511	Asthma morbidity after the short-term use of ibuprofen in children. **2002**, 109, E20	121
510	Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis. **2002**, 24, 315-21	10
509	Potential role of macrolide antibiotics in the management of cystic fibrosis lung disease. **2002**, 8, 521-8	23

508	Bradykinin increases IL-8 generation in airway epithelial cells via COX-2-derived prostanoids. **2002**, 283, L612-8	31
507	Lung infections associated with cystic fibrosis. **2002**, 15, 194-222	1158
506	Macrolides in cystic fibrosis: is there a role?. **2002**, 1, 235-41	14
505	Fibrosis qu□stica. Fisiopatolog□, gen□ica, aspectos cl□icos y terap□uticos. **2002**, 37, 1-22	
504	An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. **2002**, 34, 434-40	292
503	Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids. **2002**, 4, 381-9	10
502	Cystic Fibrosis Methods and Protocols. **2002**,	1
501	Pilot safety study of liposomal prostaglandin (PGE1) in respiratory exacerbations in cystic fibrosis. **2002**, 1, 90-3	3
500	Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. **2002**, 1, 249-54	93
499	Cystic fibrosis: a 2002 update. **2002**, 140, 156-64	76
498	Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. **2002**, 140, 439-44	50
497	Hyperacidification in cystic fibrosis: links with lung disease and new prospects for treatment. **2002**, 8, 512-9	62
496	A(2) adenosine receptors regulate CFTR through PKA and PLA(2). **2002**, 282, L12-25	53
495	Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. **2002**, 54, 1409-23	64
494	Transplantation for cystic fibrosis: outcome following early liver transplantation. **2002**, 17, 208-13	80
493	Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. **2002**, 21, 1271-87	86
492	Evidence-based medicine in cystic fibrosis: how should practice change?. **2002**, 34, 242-7	2
491	Symposium summaries S13.4□18.4. **2002**, 34, 153-181	

490	The role of inflammation in the pathophysiology of CF lung disease. **2002**, 23, 5-27	180
489	Use of modulators of airways inflammation in patients with CF. **2002**, 23, 29-39	3
488	Cystic fibrosis-related diabetes. **2003**, 20, 425-36	67
487	Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis. **2003**, 36, 427-32	36
486	Pathophysiology and management of pulmonary infections in cystic fibrosis. **2003**, 168, 918-51	1230
485	Improved glutathione status in young adult patients with cystic fibrosis supplemented with whey protein. **2003**, 2, 195-8	72
484	Cystic fibrosis. **2003**, 361, 681-9	800
483	Low-dose methotrexate for advanced pulmonary disease in patients with cystic fibrosis. **2003**, 97, 498-500	15
482	Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. **2003**, 142, 624-30	292
481	[Question 1. What is the influence of nutritional status on the progression of cystic fibrosis? Physiopathologic aspects of nutritional disorders in the course of cystic fibrosis]. **2003**, 10 Suppl 3, 413s-420s	1
480	[Anti-inflammatory therapy in cystic fibrosis]. **2003**, 10 Suppl 2, 370s-375s	
479	Newer therapies for cystic fibrosis. **2003**, 13, 259-263	3
478	[Complementary therapies in cystic fibrosis: evidence of therapeutic benefits and treatment recommendations]. **2003**, 58, 39-44	3
477	Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. **2003**, 290, 1749-56	668
476	Microarray analysis of global gene expression in mucoid Pseudomonas aeruginosa. **2003**, 185, 1071-81	135
475	Population pharmacokinetics of high dose ibuprofen in cystic fibrosis. **2003**, 88, 1128-30	9
474	Altered tissue distribution in adults with cystic fibrosis. **2003**, 58, 885-9	27
473	Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. **2003**, 306, 1086-91	71

472	Hidden depletion of fat-free mass and bone mineral density in adults with cystic fibrosis. **2003**, 124, 2220-8	57
471	Overview of cystic fibrosis and non-CF bronchiectasis. **2003**, 24, 619-28	6
470	Cor pulmonale in cystic fibrosis. **2003**, 24, 323-30	13
469	Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. **2003**, 168, 1471-5	141
468	Emerging drug treatments for cystic fibrosis. **2003**, 8, 523-35	7
467	Factors influencing outcomes in cystic fibrosis: a center-based analysis. **2003**, 123, 20-7	169
466	Early aggressive intervention in cystic fibrosis: is it time to redefine our "best practice" strategies?. **2003**, 123, 1-3	26
465	Current treatment of chronic bronchial suppuration. **2003**, 403-427	
464	Current and future treatment of cystic fibrosis. **2003**, 428-450	
463	. **2003**,	15
462	Pseudomonas aeruginosa Biofilms in Lung Infections. **2003**, 287-310	
461	Mucoactive Agents for the Treatment of Cough. 269-281	2
460	Cystic fibrosis: bench to bedside 2003. **2003**, 10, 161-4	3
459	Cytokine secretion by cystic fibrosis airway epithelial cells. **2004**, 169, 645-53	124
458	Lung inflammation as a therapeutic target in cystic fibrosis. **2004**, 31, 377-81	86
457	Primary ciliary dyskinesia: diagnostic and phenotypic features. **2004**, 169, 459-67	548
456	Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. **2004**, 169, 719-25	135
455	Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. **2004**, 170, 1331-9	107

454	Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein. **2004**, 64, 6207-13	64
453	Ibuprofen and increased morbidity in children with asthma: fact or fiction?. **2004**, 6, 267-72	8
452	New therapeutic key for cystic fibrosis: a role for lipoxins. **2004**, 5, 357-8	15
451	High-dose ibuprofen therapy associated with esophageal ulceration after pneumonectomy in a patient with cystic fibrosis: a case report. **2004**, 4, 19	11
450	Pulmonary exacerbations in cystic fibrosis. **2004**, 37, 400-6	141
449	Molecular imaging for pediatric lung diseases. **2004**, 37, 286-96	7
448	CF: an X-ray database to assess effect of aerosolized tobramycin. **2004**, 38, 23-30	14
447	Symposium summaries. **2004**, 38, 92-188	78
446	Early interventions in CF. **2004**, 26, 88-90	4
445	Comparing the efficacy of NSAIDs and paracetamol in children. **2004**, 14, 201-17	30
444	Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. **2004**, 3, 67-91	213
443	Cytokines and inflammatory mediators in cystic fibrosis. **2004**, 3, 223-31	80
442	Pharmacokinetics of Ibuprofen in children with cystic fibrosis. **2004**, 43, 145-56	4
441	NSAID-related psychiatric adverse events: who is at risk?. **2004**, 64, 2619-27	40
440	Cystic fibrosis lung disease: when does it start, and how can it be prevented?. **2004**, 145, 6-7	1
439	Effects of CFTR, interleukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell Line. **2004**, 10, 562-73	43
438	Pulmonary Effects of Low-Dose Methotrexate Therapy. **2004**, 11, 307-317	1
437	Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. **2004**, 126, 412-9	112

436	Cystic fibrosis adult care: consensus conference report. **2004**, 125, 1S-39S	394
435	Mucoviscidose. **2004**, 1, 1-14	
434	Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. **2005**, 128, 912-9	70
433	Cystic fibrosis: an overview. **2005**, 39, 307-17	30
432	Platelet activation in cystic fibrosis. **2005**, 105, 4635-41	93
431	Perioperative pharmacokinetics of ibuprofen enantiomers after rectal administration. **2005**, 15, 566-73	12
430	Effects of liver transplantation on the nutritional status of patients with cystic fibrosis. **2005**, 18, 246-55	42
429	Amphiphilic pyridinium salts block TNF alpha/NF kappa B signaling and constitutive hypersecretion of interleukin-8 (IL-8) from cystic fibrosis lung epithelial cells. **2005**, 70, 381-93	18
428	Antiinflammatory therapies for cystic fibrosis: past, present, and future. **2005**, 25, 555-73	33
427	Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. **2005**, 35, 739-57	28
426	DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. **2005**, 39, 1-4	67
425	CFTR: more than just a chloride channel. **2005**, 39, 292-8	68
424	Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy. **2005**, 40, 15-21	69
423	Anti-Inflammatory Agents. **2005**, 34, 187-194	
422	Surfactant replacement does not reduce duration of ventilatory support in paediatric acute lung injury. **2005**, 60, 325-325	78
421	The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function. **2005**, 171, 966-71	92
420	Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. **2005**, 172, 1128-32	123
419	Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. **2006**, 61, 80-5	148

418	Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. **2005**, 60, 320-5	35
417	Interleukin-1beta differentially regulates beta2 adrenoreceptor and prostaglandin E2-mediated cAMP accumulation and chloride efflux from Calu-3 bronchial epithelial cells. Role of receptor changes, adenylyl cyclase, cyclo-oxygenase 2, and protein kinase A. **2005**, 280, 23451-63	22
416	Assessment of hypoxia in children with cystic fibrosis. **2005**, 90, 1138-43	37
415	Cystic fibrosis, disease severity, and a macrophage migration inhibitory factor polymorphism. **2005**, 172, 1412-5	73
414	Diabetes: a major co-morbidity of cystic fibrosis. **2005**, 31, 221-32	80
413	Use of macrolides and tetracyclines for chronic inflammatory diseases. **2005**, 39, 86-94	37
412	Development of medicines for children in Europe: ethical implications. **2005**, 6, 45-51	23
411	Relation of exaggerated cytokine responses of CF airway epithelial cells to PAO1 adherence. **2005**, 6, 69	12
410	Docosahexaenoic acid trials in cystic fibrosis: a review of the rationale behind the clinical trials. **2005**, 4, 27-34	15
409	Disease-specific reference equations for lung function in patients with cystic fibrosis. **2005**, 172, 885-91	56
408	Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. **2005**, 4, 255-73	27
407	Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. **2005**, 151, 373-383	389
406	Cystic fibrosis pulmonary exacerbations. **2006**, 148, 259-64	109
405	What's new in CF airway inflammation: an update. **2006**, 7 Suppl 1, S70-2	24
404	CF-Emerging therapies: Modulation inflammation. **2006**, 7 Suppl 1, S170-4	10
403	Mucoviscidose´: physiopathologie, g□□ique, aspects cliniques et th□apeutiques. **2006**, 1, 1-23	
402	Advances in cystic fibrosis therapies. **2006**, 18, 604-13	37
401	Mucoviscidosis (Cystic Fibrosis), Molecular Cell Biology of. **2006**,	

400	High resolution computerized tomography of the chest and pulmonary function testing in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis patients. **2006**, 41, 1129-37	18
399	Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8). **2006**, 23, 1209-16	36
398	Zystische Fibrose. **2006**, 3, 325-339	0
397	Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. **2006**, 25, 418-27	67
396	A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients. **2006**, 6, 17	14
395	Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. **2006**, 50, 2293-9	34
394	Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. **2006**, 173, 1363-9	85
393	Adenosine regulation of cystic fibrosis transmembrane conductance regulator through prostenoids in airway epithelia. **2006**, 34, 600-8	41
392	Inhaled heparin in cystic fibrosis. **2006**, 27, 354-8	32
391	Inflammation is a modulator of the insulin-like growth factor (IGF)/IGF-binding protein system inducing reduced bioactivity of IGFs in cystic fibrosis. **2006**, 154, 47-52	54
390	COX-2: a link between airway inflammation and disordered chloride secretion in cystic fibrosis?. **2006**, 61, 552-3	6
389	Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome. **2006**, 317, 275-83	31
388	Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. **2006**, 57, 741-6	79
387	Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. **2006**, 61, 592-6	29
386	FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. **2006**, 100, 1602-9	68
385	The inflammatory role of platelets in cystic fibrosis. **2006**, 173, 483-90	64
384	Improving rate of decline of FEV1 in young adults with cystic fibrosis. **2006**, 61, 155-7	82
383	Novel pharmaceutical approaches for treating patients with cystic fibrosis. **2007**, 13, 3252-63	7

382	Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. **2007**, CD001505	32
381	Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. **2007**, 36, 728-36	109
380	Ibuprofen therapy and nasal polyposis in cystic fibrosis patients. **2007**, 36, 309-14	23
379	Advancing outcome measures for the new era of drug development in cystic fibrosis. **2007**, 4, 370-7	43
378	Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. **2007**, 132, 1212-8	44
377	IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. **2007**, 292, L519-28	154
376	Inflammation in cystic fibrosis--when and why? Friend or foe?. **2007**, 28, 286-94	7
375	Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. **2007** , 176, 1084-9	144
374	Heritability of lung disease severity in cystic fibrosis. **2007**, 175, 1036-43	147
373	Pharmacotherapy for bronchiectasis. **2007**, 8, 3183-93	5
372	Exacerbations in cystic fibrosis: 2 . prevention. **2007**, 62, 723-32	33
371	Pulmonary exacerbations in cystic fibrosis and bronchiectasis. **2007**, 62, 288-90	17
370	Dysphonia. **2007**, 46, 283-5	1
369	Azithromycin protects against hyperoxic lung injury in neonatal rats. **2007**, 55, 299-305	19
368	The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. **2007**, 67, 3254-62	48
367	Nutrition in pediatric lung disease. **2007**, 8, 305-11; quiz 312	6
366	Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. **2007**, 77, 309-18	36
365	[Treatment of airway inflammation in cystic fibrosis]. **2007**, 14, 1350-5	1

364	A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthma-related symptoms. **2007**, 29, 2716-23	37
363	Actualités thérapeutiques 2007 dans la mucoviscidose. **2007**, 24, 109-111	
362	Inflammation and anti-inflammatory therapies for cystic fibrosis. **2007**, 28, 331-46	78
361	Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. **2007**, 176, 957-69	502
360	Pseudomonas aeruginosa and the host pulmonary immune response. **2007**, 1, 121-37	5
359	Use of high-dose ibuprofen in a pediatric cystic fibrosis center. **2007**, 6, 153-8	27
358	Bioelectric effects of quinine on polarized airway epithelial cells. **2007**, 6, 351-9	4
357	Clinical trials in cystic fibrosis. **2007**, 6, 85-99	37
356	Sputum biomarkers of inflammation in cystic fibrosis lung disease. **2007**, 4, 406-17	122
355	Pharmacologic, pharmacodynamic, and pharmacokinetic considerations with intravenous Ibuprofen lysine. **2007**, 12, 158-70	2
354	Abstracts of the 21st Annual North American Cystic Fibrosis Conference, October 3-6, 2007, Anaheim, California, USA. **2007**, 30, 99-412	
353	Recurrent Pseudomonas bronchopneumonia and other symptoms as in cystic fibrosis in a child with type I pseudohypoaldosteronism. **2007**, 87, 472-474	28
352	50 Years Ago in The Journal of Pediatrics. **2007**, 151, 139	
351	Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. **2007**, 151, 134-9, 139.e1	328
350	Pacing the marathon: rate of decline of pulmonary function in cystic fibrosis. **2007**, 151, 111-3	4
349	High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. **2007**, 151, 249-54	114
348	Non! to non-steroidal anti-inflammatory therapy for inflammatory lung disease in cystic fibrosis (at least at the moment). **2007**, 151, 228-30	15
347	Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?. **2007**, 166, 23-8	28

346	Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. **2008**, 34, 146-62	86
345	Anti-inflammatory therapies for cystic fibrosis-related lung disease. **2008**, 35, 135-53	30
344	What's new in cystic fibrosis? From treating symptoms to correction of the basic defect. **2008**, 167, 839-49	57
343	Dornase alfa and progression of lung disease in cystic fibrosis. **2008**, 43, S24-S28	5
342	A role for aerosolized antibiotics. **2008**, 43, S29-S34	5
341	Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. **2008**, 153, 746-51	65
340	Association between practice patterns and body mass index percentile in infants and young children with cystic fibrosis. **2008**, 7, 385-90	3
339	Recent advances in cystic fibrosis. **2008**, 9, 144-8	31
338	Clinical trials in infants with cystic fibrosis detected following newborn screening. **2008**, 9, 176-80	3
337	Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. **2008**, 78, 109-15	47
336	Cystic fibrosis: a review of pulmonary and nutritional therapies. **2008**, 55, 99-121	7
335	Proteases and cystic fibrosis. **2008**, 40, 1238-45	144
334	Neutrophils in cystic fibrosis. **2009**, 64, 81-8	142
333	Respiratory Manifestations. **2008**, 871-887	1
332	Intensive care management of the patient with cystic fibrosis. **2008**, 23, 159-77	11
331	Inhibition of airway proteases in cystic fibrosis lung disease. **2008**, 32, 783-95	79
330	Airway inflammation in cystic fibrosis. **2008**, 133, 489-95	182
329	Assessment and monitoring of cystic fibrosis lung disease in infants and young children. **2008**, 2, 381-90	

328	Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis. **2008**, 5, 29-33	19
327	Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium. **2008**, 295, L303-13	48
326	Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. **2008**, 178, 814-21	243
325	Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR. **2008**, 32, 334-43	18
324	Cystic fibrosis papers of the year 2007. **2008**, 101 Suppl 1, S10-4	1
323	Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. **2008**, 180, 7764-73	71
322	Cystic fibrosis lung disease in adult patients. **2008**, 120, 64-74	6
321	CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells. **2008**, 38, 176-84	51
320	Ibuprofen therapy for cystic fibrosis lung disease: revisited. **2008**, 14, 567-73	49
319	End of life care in chronic obstructive pulmonary disease: in search of a good death. **2008**, 3, 11-29	46
318	Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. **2008**, 14, 378-84	148
317	NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. **2009**, 8, 261-73	36
316	A pipeline of therapies for cystic fibrosis. **2009**, 30, 611-26	22
315	The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. **2009**, 297, L828-36	36
314	The clinical approach to lung disease in patients with cystic fibrosis. **2009**, 30, 505-13	28
313	Stabilization of lung function and clinical symptoms in a patient with cystic fibrosis (CF) after institution of infliximab: a monoclonal antibody that binds tumor necrosis factor alpha. **2009**, 187, 149-52	9
312	Ibuprofen: pharmacology, efficacy and safety. **2009**, 17, 275-342	302
311	Symposium Summaries. **2009**, 44, 109-212	5

310	Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. **2009**, 8, 1-8	14
309	Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. **2009**, 8, 295-315	193
308	[Protocol for the diagnosis and follow up of patients with cystic fibrosis]. **2009**, 71, 250-64	11
307	Bronchiectasis in children. **2009**, 56, 157-71, xi	20
306	The role of inhaled corticosteroids in the management of cystic fibrosis. **2009**, 11, 101-13	31
305	Characterizing aggressiveness and predicting future progression of CF lung disease. **2009**, 8 Suppl 1, S15-9	41
304	Cystic fibrosis. **2009**, 373, 1891-904	972
303	A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. **2009**, 14, 352-8	34
302	Inflammation, Hyperinflammation & Cystic Fibrosis Lung Disease A Paradigm Shift?. **2009**, 5, 136-148	
301	New Genetic and Pharmacological Treatments for Cystic Fibrosis. **2009**, 5, 8-27	2
300	Update on new pulmonary therapies. **2009**, 15, 604-10	4
299	Prostaglandin-endoperoxide synthase genes COX1 and COX2 - novel modifiers of disease severity in cystic fibrosis patients. **2010**, 51, 323-30	13
298	Protracted bacterial bronchitis (PBB). **2010**, 11, S71-S73	
297	Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. **2010**, 125, 219-29	45
296	Ibuprofen for neuroprotection after cerebral ischemia. **2010**, 139, 489-93	14
295	Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. **2010**, 40, 239-47	78
294	Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?. **2010**, 45, 107-17	126
293	Real-time, once-daily monitoring of symptoms and FEV in cystic fibrosis patients--a feasibility study using a novel device. **2010**, 4, 74-82	19

292	Potential of anti-inflammatory treatment for cystic fibrosis lung disease. **2010**, 3, 61-74	11
291	Pediatric Respiratory Assembly. Mini symposium on lung inflammation. **2010**, 17, e35-41	
290	High-Dose Ibuprofen in Cystic Fibrosis. **2010**, 3, 2213-2224	18
289	A disease-relevant high-content screening assay to identify anti-inflammatory compounds for use in cystic fibrosis. **2010**, 15, 1204-10	7
288	Molecular Basis of Pulmonary Disease. **2010**,	3
287	Improving evidence-based care in cystic fibrosis through quality improvement. **2010**, 164, 957-60	22
286	TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. **2010**, 185, 7731-8	56
285	In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an innate neutrophil disturbance. **2010**, 2, 260-6	71
284	Platelet proinflammatory activity in clinically stable patients with CF starts in early childhood. **2010**, 9, 179-86	10
283	Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. **2010**, 9, 332-8	35
282	Dietary supplementation with pressurized whey in patients with cystic fibrosis. **2010**, 13, 77-82	31
281	Emerging therapies in cystic fibrosis. **2010**, 4, 177-85	31
280	Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. **2010**, 14, 117-30	95
279	Consequences of airway neutrophilia in children. **2010**, 11, S67-S71	
278	Ibuprofen modulates NF-kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells. **2010**, 79, 234-42	28
277	Clinical significance of microbial infection and adaptation in cystic fibrosis. **2011**, 24, 29-70	271
276	Targeting airway inflammation in cystic fibrosis in children: past, present, and future. **2011**, 13, 141-7	18
275	Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. **2011**, 183, 1463-71	207

274	Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. **2011**, 105 Suppl 2, S18-23	14
273	Pain is a common problem affecting clinical outcomes in adults with cystic fibrosis. **2011**, 140, 1598-1603	40
272	Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study. **2011**, 65, 102-9	61
271	Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells. **2011**, 650, 170-7	20
270	The cystic fibrosis neutrophil: a specialized yet potentially defective cell. **2011**, 59, 97-112	61
269	Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. **2011**, 46, 545-53	66
268	Update in cystic fibrosis 2010. **2011**, 183, 1620-4	16
267	Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis. **2011**, 37, 1091-5	23
266	Down-regulation of cytokine-induced interleukin-8 requires inhibition of p38 mitogen-activated protein kinase (MAPK) via MAPK phosphatase 1-dependent and -independent mechanisms. **2011**, 286, 15998-6007	24
265	Platelets in pulmonary vascular physiology and pathology. **2012**, 2, 291-308	33
264	Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. **2012**, 40, 61-6	146
263	Integrative Therapies in Lung Health and Sleep. **2012**,	
262	Progressive flow-to-volume dysanapsis in cystic fibrosis: a predictor for lung transplantation?. **2012**, 186, 82-7	16
261	Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. **2012**, 2, 163-175	28
260	Atypical activation of the unfolded protein response in cystic fibrosis airway cells contributes to p38 MAPK-mediated innate immune responses. **2012**, 189, 5467-75	51
259	New therapies in cystic fibrosis. **2012**, 18, 614-27	19
258	Progress in cystic fibrosis and the CF Therapeutics Development Network. **2012**, 67, 882-90	49
257	Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. **2012**, 11, 78-83	52

256	State of progress in treating cystic fibrosis respiratory disease. **2012**, 10, 88	46
255	Pulmonary Disease in Cystic Fibrosis. **2012**, 770-780	6
254	Ibuprofen: Pharmacology, Therapeutics and Side Effects. **2012**,	18
253	The Prognosis of Cystic Fibrosis - A Clinician Perspective. **2012**,	
252	Channel Replacement Therapy for Cystic Fibrosis. **2012**,	0
251	Liver transplantation in chronic cholestatic conditions. **2012**, 17, 959-69	12
250	Cystic fibrosis: a mucosal immunodeficiency syndrome. **2012**, 18, 509-19	336
249	Pathogenesis and management of nasal polyposis in cystic fibrosis. **2012**, 12, 163-74	52
248	Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. **2012**, 53, 160-71	106
247	Enhancement of anti-inflammatory drug activity by multivalent adamantane-based dendrons. **2012**, 33, 5610-7	26
246	CFTR negatively regulates cyclooxygenase-2-PGE(2) positive feedback loop in inflammation. **2012**, 227, 2759-66	36
245	R-flurbiprofen, a novel nonsteroidal anti-inflammatory drug, decreases cell proliferation and induces apoptosis in pituitary adenoma cells in vitro. **2012**, 106, 561-9	14
244	Mechanism and Causality in Biology and Economics. **2013**,	3
243	New advances in the therapy of non-cystic fibrosis bronchiectasis. **2013**, 19, 266-275	5
242	Is adolescents religious coping with cystic fibrosis associated with the rate of decline in pulmonary function?-A preliminary study. **2013**, 19, 33-42	12
241	Cystic fibrosis therapeutics: the road ahead. **2013**, 143, 207-213	65
240	Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. **2013**, 12, 241-8	84
239	FDG PET imaging in cystic fibrosis. **2013**, 43, 412-9	12

238	New advances in the therapy of non-cystic fibrosis bronchiectasis. **2013**, 19, 266-75		7
237	Early lung disease in cystic fibrosis. **2013**, 1, 148-57		58
236	Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. **2013**, 187, 680-9		432
235	Risk factors for bronchiectasis in children with cystic fibrosis. *New England Journal of Medicine*, **2013**, 368, 1963-70	59.2	369
234	Synthesis and Spectrophotometric Determination Ibuprofen Charge Transfer Complexes with P-Chloranil, 7,7,8,8-Tetracyanoquinodimethane, Bromothymol Blue, Methyl Orange and Picric Acid. **2013**, 05,		
233	Antibiotic and anti-inflammatory therapies for cystic fibrosis. **2013**, 3, a009779		40
232	Oral contraceptives do not appear to affect cystic fibrosis disease severity. **2013**, 41, 67-73		17
231	The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients. **2013**, 48, 1181-9		8
230	Induction of cyclooxygenase-2 signaling by Stomatococcus mucilaginosus highlights the pathogenic potential of an oral commensal. **2013**, 191, 3810-7		13
229	Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. **2013**, CD001505		23
228	Anti-inflammatory therapies for cystic fibrosis lung disease. **2013**, 82-92		
227	Important role of platelets in modulating endotoxin-induced lung inflammation in CFTR-deficient mice. **2013**, 8, e82683		12
226	Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis. **2014**, 6, 94		16
225	Histatins: salivary peptides with copper(II)- and zinc(II)-binding motifs: perspectives for biomedical applications. **2014**, 281, 657-72		76
224	What is the optimal management of chronic rhinosinusitis in cystic fibrosis?. **2014**, 22, 42-6		11
223	Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. **2014**, 47, 539-46		40
222	High-dose ibuprofen is not associated with increased biomarkers of kidney injury in patients with cystic fibrosis. **2014**, 49, 148-53		21
221	Symposium Session Summaries. **2014**, 49, S116-S215		1

220	Dissecting the reaction of Phase II metabolites of ibuprofen and other NSAIDS with human plasma protein. **2014**, 5, 3789-3794	14
219	Pediatric Chest Imaging. **2014**,	1
218	Risk factors for the progression of cystic fibrosis lung disease throughout childhood. **2014**, 11, 63-72	47
217	A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. **2014**, 13, 148-55	93
216	Advances in the diagnosis and treatment of cystic fibrosis. **2014**, 61, 225-43	10
215	Thoracic Manifestations of Systemic Diseases. **2014**, 395-429	1
214	Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics. **2015**, 50 Suppl 40, S66-73	6
213	Symposium Summaries. **2015**, 50 Suppl 41, S108-92	1
212	Pharmacology and Toxicology of Ibuprofen. **2015**, 132-236	2
211	Essential oils in the treatment of respiratory tract diseases highlighting their role in bacterial infections and their anti-inflammatory action: a review. **2015**, 30, 331-341	44
210	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. **2015**, 50, 856-62	13
209	Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. **2015**, 50, 763-70	71
208	Gene expression profile of ABC transporters and cytotoxic effect of ibuprofen and acetaminophen in an epithelial ovarian cancer cell line in vitro. **2015**, 37, 283-90	8
207	Genetic Deletion and Pharmacological Inhibition of PI3K Reduces Neutrophilic Airway Inflammation and Lung Damage in Mice with Cystic Fibrosis-Like Lung Disease. **2015**, 2015, 545417	13
206	Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. **2015**, 14, 720-6	43
205	The Evolution of Cystic Fibrosis Care. **2015**, 148, 533-542	32
204	Spanish consensus on the prevention and treatment of Pseudomonas aeruginosa bronchial infections in cystic fibrosis patients. **2015**, 51, 140-50	29
203	The challenges of developing effective anti-inflammatory agents in cystic fibrosis. **2015**, 14, 164-6	6

202	[Cystic fibrosis and associated complications]. **2015**, 56, 263-74	2
201	Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients. **2015**, 51, 140-150	4
200	Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. **2015**, 14, 228-36	29
199	Cystic fibrosis. **2015**, 1, 15010	258
198	Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. **2015**, 12, 1398-406	28
197	Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. **2015**, 14, 219-27	73
196	42-year-old man with asthma symptoms and recurrent bronchitis. **2015**, 90, 527-31	
195	Pulmonary function outcomes for assessing cystic fibrosis care. **2015**, 14, 376-83	11
194	Chiral liquid membrane for enantioselective separation of racemic ibuprofen by L-tartaric acid derivatives. **2015**, 5, 41729-41735	12
193	Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. **2015**, 14, 419-30	276
192	Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. **2015**, 14, 763-9	30
191	Public health evolutionary biology of antimicrobial resistance: priorities for intervention. **2015**, 8, 223-39	37
190	Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. **2015**, 9, 313-26	52
189	Ibuprofen. **2016**, 5-12	
188	Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. **2016**, 4, CD001505	20
187	Current Concepts and Controversies in Innate Immunity of Cystic Fibrosis Lung Disease. **2016**, 8, 531-540	23
186	Neutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway disease. **2016**, 3, 38	22
185	Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. **2016**, 311, L317-27	17

184	New and emerging targeted therapies for cystic fibrosis. **2016**, 352, i859	91
183	Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications. **2016**, 7, 170-83	31
182	Key mechanisms governing resolution of lung inflammation. **2016**, 38, 425-48	138
181	Handbook of Cystic Fibrosis. **2016**,	4
180	Treatment of Cystic Fibrosis. **2016**, 77-99	1
179	Background and Epidemiology. **2016**, 63, 567-84	43
178	Cystic Fibrosis: Microbiology and Host Response. **2016**, 63, 617-36	23
177	Improved Efficiency of Ibuprofen by Cationic Carbosilane Dendritic Conjugates. **2016**, 13, 3427-3438	12
176	Biomarkers for cystic fibrosis drug development. **2016**, 15, 714-723	46
175	Aminoglycoside antibiotics. **2016**, 216-236	0
174	Carrier-free high-dose dry powder inhaler formulation of ibuprofen: Physicochemical characterization and in vitro aerodynamic performance. **2016**, 511, 403-414	23
173	Question 5: What is the role of macrolide antibiotics as anti-inflammatory treatment in Cystic fibrosis?. **2016**, 18, 55-57	
172	CFTR and Cystic Fibrosis. **2016**, 519-552	3
171	Cystic Fibrosis and Its Management Through Established and Emerging Therapies. **2016**, 17, 155-75	28
170	Using Cystic Fibrosis Therapies for Non-Cystic Fibrosis Bronchiectasis. **2016**, 37, 139-46	8
169	Cystic Fibrosis. **2016**, 822-852.e17	4
168	Bronchiectasis. **2016**, 853-876.e9	3
167	Use of FEV in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher. **2017**, 16, 318-326	54

166	Anti-Inflammatory Therapies for Cystic Fibrosis. **2017**, 139-151	3
165	AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis. **2017**, 195, 1092-1099	13
164	Working Towards an Appropriate Use of Ibuprofen in Children: An Evidence-Based Appraisal. **2017**, 77, 1295-1311	37
163	Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. **2017**, 61,	15
162	The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis. **2017**, 46, e139-e164	9
161	Medical and Surgical Advancements in the Management of Cystic Fibrosis Chronic Rhinosinusitis. **2017**, 5, 24-34	28
160	A little CFTR can change a lot: slowing cystic fibrosis progression. **2017**, 5, 86-87	4
159	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. **2017**, 5, 107-118	158
158	Comparison of FEV reference equations for evaluating a cystic fibrosis therapeutic intervention. **2017**, 52, 1013-1019	6
157	Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers. **2017**, 52, S21-S28	7
156	Corticosteroid-resistant inflammatory signalling in -infected bronchial cells. **2017**, 3,	3
155	Association of Acetaminophen and Ibuprofen Use With Wheezing in Children With Acute Febrile Illness. **2017**, 51, 239-244	6
154	Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. **2017**, 10, 28-34	33
153	Neutrophils. **2017**, 253-272	
152	Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. **2017**, 43, 219-245	39
151	Effect of inhaled steroids on clinical and inflammatoryparameters in children with cystic fibrosis. **2017**, 47, 1432-1440	2
150	Reference percentiles of FEV1 for the Canadian cystic fibrosis population: comparisons across time and countries. **2018**, 73, 446-450	5
149	Ajulemic acid: potential treatment for chronic inflammation. **2018**, 6, e00394	39

148	Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. **2018**, 15, 485-493	38
147	Increased platelet activation occurs in cystic fibrosis patients and correlates to clinical status. **2018**, 162, 32-37	14
146	Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens. **2018**, 62,	26
145	KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. **2018**, 17, 484-491	41
144	Impact of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator on high-dose ibuprofen therapy in pediatric cystic fibrosis patients. **2018**, 53, 1035-1039	5
143	The Long and the Short of It in Cystic Fibrosis Clinical Research Outcomes. **2018**, 15, 430-431	
142	Formulation and delivery strategies of ibuprofen: challenges and opportunities. **2018**, 44, 173-183	52
141	Infectious Complications in Special Hosts. **2018**, 643-651.e3	
140	Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?. **2018**, 6, 69-84	2
139	Rapid therapeutic advances in CFTR modulator science. **2018**, 53, S4-S11	27
138	Symposium Summaries. **2018**, 53, S36-S147	0
137	Omega-3 PUFA vs. NSAIDs for Preventing Cardiac Inflammation. **2018**, 5, 146	3
136	Risks associated with lung transplantation in cystic fibrosis patients. **2018**, 12, 893-904	2
135	Induced pluripotent stem cells for treating cystic fibrosis: State of the science. **2018**, 53, S12-S29	16
134	EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics. **2018**, 72, 86-94	24
133	High Concentrations of Sodium Chloride Improve Microbicidal Activity of Ibuprofen against Common Cystic Fibrosis Pathogens. **2018**, 11,	8
132	Inflammation in cystic fibrosis: An update. **2018**, 53, S30-S50	106
131	Giants in Chest Medicine: Professor Pamela B. Davis, MD, PhD. **2018**, 154, 240-241	

130	Unmet needs in cystic fibrosis: the next steps in improving outcomes. **2018**, 12, 585-593	15
129	Pulmonary Disease in Cystic Fibrosis. **2019**, 777-787.e4	3
128	A specialized method of sputum collection and processing for therapeutic interventions in cystic fibrosis. **2019**, 18, 203-211	8
127	Cystic Fibrosis: an Update on Disease Pathophysiology, Management, and Novel Modalities of Therapy. **2019**, 6, 226-237	
126	Acute Pulmonary Exacerbations in Cystic Fibrosis. **2019**, 40, 792-803	15
125	Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators. **2019**, 54 Suppl 3, S46-S55	14
124	Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction. **2019**, 40, 751-761	
123	Targeting airway inflammation in cystic fibrosis. **2019**, 13, 1041-1055	10
122	Recombinant Human Deoxyribonuclease I. **2019**, 471-488	3
121	Acetyl-CoA carboxylase inhibition regulates microtubule dynamics and intracellular transport in cystic fibrosis epithelial cells. **2019**, 316, L1081-L1093	3
120	Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients. **2019**, 20, 290	9
119	Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. **2019**, 9, CD001505	20
118	Stem Cell-Based Therapy for Lung Disease. **2019**,	3
117	Physiological study of pulmonary involvement in adults with cystic fibrosis through simulated modeling of different clinical scenarios. **2019**, 57, 413-425	0
116	Azithromycin is the answer in paediatric respiratory medicine, but what was the question?. **2020**, 34, 67-74	10
115	Strong toll-like receptor responses in cystic fibrosis patients are associated with higher lung function. **2020**, 19, 608-613	2
114	Cystic Fibrosis and Genotype-Dependent Therapy: Is There a Need for a Sex-Specific Therapy?. **2020** , 4, 247028972093702	0
113	Targeting the Heme Oxygenase 1/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis. **2020**, 11, 1059	11

112	Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution. **2020**, 144, 110079	8
111	Preparation, characterization and improved release profile of ibuprofen-phospholipid association. **2020**, 60, 101951	10
110	Cystic fibrosis - Ten promising therapeutic approaches in the current era of care. **2020**, 29, 1107-1124	4
109	Selectively targeting key inflammatory pathways in cystic fibrosis. **2020**, 206, 112717	2
108	Role of Cystic Fibrosis Bronchial Epithelium in Neutrophil Chemotaxis. **2020**, 11, 1438	9
107	The Pseudomonas aeruginosa protease LasB directly activates IL-1**2020**, 60, 102984	7
106	Pharmacological and Genomic Approaches in Management of Cystic Fibrosis. **2020**, 30, 191-197	0
105	Evaluation of a five-year predicted survival model for cystic fibrosis in later time periods. **2020**, 10, 6602	3
104	Building global development strategies for cf therapeutics during a transitional cftr modulator era. **2020**, 19, 677-687	8
103	Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease. **2020**, 11, 1011	4
102	The Resolution Approach to Cystic Fibrosis Inflammation. **2020**, 11, 1129	2
101	Resveratrol restores intracellular transport in cystic fibrosis epithelial cells. **2020**, 318, L1145-L1157	1
100	Evaluation of airway and circulating inflammatory biomarkers for cystic fibrosis drug development. **2021**, 20, 50-56	0
99	Role of the COX2-PGE axis in -induced exacerbation of experimental fibrosis. **2021**, 320, L377-L392	2
98	Drug development for cystic fibrosis. **2021**, 56 Suppl 1, S10-S22	1
97	Novel Immunomodulatory Therapies for Respiratory Pathologies. **2021**,	
96	Ibuprofen-based advanced therapeutics: breaking the inflammatory link in cancer, neurodegeneration, and diseases. **2021**, 53, 100-121	2
95	Untapped Potential: Therapeutically Targeting Eicosanoids and Endocannabinoids in the Lung. **2021**, 110, 69-81	1

94	Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches. **2021**, 22,	3
93	Cystic Fibrosis Lung Disease in the Aging Population. **2021**, 12, 601438	3
92	Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action. **2021**, 16, e0249687	2
91	Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. **2021**, 10,	3
90	Antimicrobial Effects of Ibuprofen Combined with Standard of Care Antimicrobials against Cystic Fibrosis Pathogens.	
89	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. **2021**, 902, 174098	0
88	The indispensable role of pharmacy services and medication therapy management in cystic fibrosis. **2021**,	
87	Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program. **2021**, 10, 2511-2524	2
86	Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. **2021**, 20, 1026-1034	2
85	Current and Emerging Therapies to Combat Cystic Fibrosis Lung Infections. **2021**, 9,	2
84	Serious infectious events and ibuprofen administration in pediatrics: a narrative review in the era of COVID-19 pandemic. **2021**, 47, 20	4
83	Platelets in Pulmonary Vascular Physiology and Pathology. **2011**, 371-384	1
82	Recombinant Human Deoxyribonuclease I. **2013**, 321-336	4
81	Cystic Fibrosis. **1998**, 329-338	1
80	Integrative Therapies for People with Cystic Fibrosis. **2012**, 113-126	3
79	Therapeutic Approaches to the Lung Problems in Cystic Fibrosis. **1997**, 341-364	1
78	Nasal Polyps in Cystic Fibrosis. **2010**, 145-152	1
77	Mechanisms Versus Causes in Biology and Medicine. **2013**, 19-34	10

76	Therapeutic drug monitoring by capillary electrophoresis. **1997**, 386-408	3
75	Pulmonary Disease in Cystic Fibrosis. **2006**, 873-886	3
74	Cystic Fibrosis. **2010**, 985-1022	6
73	Bronchiectasis. **2010**, 1023-1046	2
72	Cystic Fibrosis. **2015**, 874-885.e3	1
71	Malnutrition in children with cystic fibrosis: the energy-balance equation. **1997**, 25, 127-36	22
70	Diffuse microcystic pancreatic enlargement in a cystic fibrosis patient causing severe gastrointestinal symptoms and successfully treated by total pancreatectomy. **1998**, 26, 454-7	1
69	The effect of intestinal permeability on pancreatic enzyme-induced enteropathy in the rat. **1998**, 26, 489-95	15
68	The effects of high-dose ibuprofen and pancreatic enzymes on the intestine of the rat. **1999**, 29, 178-83	5
67	Role of Inflammasome-independent Activation of IL-1 by the Pseudomonas aeruginosa Protease LasB.	2
66	Pseudomonas aeruginosa Infections. 305-326	5
65	Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation. **2020**, 130, 2041-2053	20
64	Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion. **1998**, 102, 679-87	29
63	Taxonomy of Mucoactive Medications. **2004**, 129-145	5
62	Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. **1997**, 41, 161-5	69
61	Cyclooxygenase-2 promotes ovarian cancer cell migration and cisplatin resistance via regulating epithelial mesenchymal transition. **2020**, 21, 315-326	4
60	New developments in cystic fibrosis. **1998**, 27, 515-20	8
59	Anti-Inflammatory Therapy of Infections. **2021**,	

58	Increasing life expectancy in cystic fibrosis: Advances and challenges. **2021**,	4
57	Myeloperoxidase Activity of Neutrophils in Cystic Fibrosis. **2000**, 107-113	
56	Serum Drug Monitoring by Capillary Electrophoresis. **2001**, 355-383	1
55	Atemwegserkrankung. **2001**, 265-366	
54	Infektionen der unteren Atemwege. **2004**, 243-300	
53	Zystische Fibrose. **2004**, 966-996	
52	Cystic Fibrosis. **2005**, 116-130	1
51	Cystic Fibrosis. **2007**, 494-501	
50	Infectious Complications in Special Hosts. **2008**, 633-641	
49	Thoracic Manifestations of Systemic Diseases. **2008**, 289-312	
48	CYSTIC FIBROSIS. **2009**, 342-364	
47	Cystic Fibrosis. **2010**, 947-955	1
46	Cystic Fibrosis. **2010**, 339-368	
45	Cystic Fibrosis. **2010**, 1037-1044.e2	
44	The Respiratory System. **2012**, 321-394	
43	Biodisposition in Relation to Actions. **2012**, 5-42	
42	Infectious Complications in Special Hosts. **2012**, 633-641.e4	
41	Cystic Fibrosis Needs Attention in Iran. **2013**, 2, 107-8	

40 The many uses of ibuprofen. **1996**, 21, 56

39 The General Approach to Cystic Fibrosis-Related Pulmonary Infection in the United States. **1996**, 99-110

38 Mucoactive Agents: Old and New. **1997**, 155-179 2

37 Anti-inflammatory Therapies for Chronic Lung Diseases in Children. **1997**, 113-136

36 Cystic Fibrosis. **1998**, 223-232

35 Obstructive Pulmonary Diseases. **1999**, 185-225

34 Rational treatment of pulmonary infections in patients with cystic fibrosis. **1999**, 12, 257-63 1

33 Human Toxicity of Ibuprofen. 498-517

32 Clinical Application of Stem/Stromal Cells in Cystic Fibrosis. **2019**, 179-198

31 CYSTIC FIBROSIS: A BREAKTHROUGH IN 21ST-CENTURY THERAPY. **2020**, 23, 35-41

30 Drug Repurposing Through a Bioinformatics Pipeline Applied on Fibrotic Diseases.

29 Inflammation in CF: Key Characteristics and Therapeutic Discovery. **2020**, 161-179 1

28 Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages. **2021**, 57, 2

27 Cystic fibrosis. **2020**, 4151-4165

26 Current evidence on the effect of highly effective CFTR modulation on interleukin-8 in cystic fibrosis. **2021**, 1-14 0

25 Cystic Fibrosis. **2006**, 251-258

24 Role of corticosteroids in cystic fibrosis lung disease. **1996**, 89 Suppl 27, 8-13 4

23 Liver transplantation for hepatic cirrhosis in cystic fibrosis. **1996**, 89 Suppl 27, 31-7 9

22	Cystic fibrosis in adults. From researcher to practitioner. **1996**, 164, 321-34	6
21	Understanding non-compliance with treatment in adults with cystic fibrosis. **2000**, 93 Suppl 38, 2-8	12
20	New therapeutic approaches for cystic fibrosis lung disease. **2002**, 95 Suppl 41, 58-67	1
19	Recent Progress on Ultra-Small Nanostructure Materials as Fluorescent Nanosensors for Monitoring of Various Molecules in Environmental Samples.	
18	Xylitol as a Hydrophilization Moiety for a Biocatalytically Synthesized Ibuprofen Prodrug.. **2022**, 23,	1
17	Ultrasound-Assisted Slug-Flow Tubular Crystallization for Preparation of Fine Ibuprofen Crystals.	0
16	The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.. **2022**, 23,	2
15	Cystic Fibrosis Mucus Model to Design More Efficient Drug Therapies.. **2021**,	3
14	Losartan ameliorates TGF-β1-induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies.. **2022**,	1
13	İbuprofenin Farmasötik Preperatlarda UPLC-MS/MS Yöntemiyle Tayini.	
12	TREATMENT OF STEROID-RESISTANT ASTHMA. **1996**, 16, 777-796	
11	Is CF airway inflammation still relevant in the era of highly effective modulators?. **2022**,	
10	Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.	0
9	Cystic Fibrosis. **2022**,	1
8	Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis. **2022**, 43, 617-630	0
7	Infectious Complications in Special Hosts. **2023**, 665-673.e4	0
6	Advances in Ultra-small Fluorescence Nanoprobes for Detection of Metal Ions, Drugs, Pesticides and Biomarkers.	1
5	Lessons from other fields of medicine, Part 2: Cystic fibrosis. **2023**, 119-130	0

4	Diagnosis and Management of Cystic Fibrosis Exacerbations. **2023**, 44, 225-241	0
3	Preparation and Characterization of Ibuprofen Containing Nano-Embedded-Microparticles for Pulmonary Delivery. **2023**, 15, 545	0
2	High efficiency removal of ibuprofen in water using activated carbon derived from Radix Angelica Dahurica residue.	0
1	Inflammation as a Regulator of the Airway Surface Liquid pH in Cystic Fibrosis. **2023**, 12, 1104	0